# A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct06084936/  
OnCo record `nct06084936` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT06084936 by Hoffmann-La Roche, with 182 participants planned, started 2023-10-22 and due to reach its primary completion in 2027-08-31. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06084936
- Phase: 3
- Setting: A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 182

## Sources

- ClinicalTrials.gov NCT06084936: https://clinicaltrials.gov/study/NCT06084936

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct06084936.json